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Summary
In recent years, there have been exciting new insights into pathogenesis of type 
1 diabetes in a number of areas of immunology. In this edition, a collection of 
four review articles are presented, which encompass new findings presented at the 
Immunology of Diabetes Society meeting in London 2018. The articles are focused 
particularly in 4 related areas of investigation, which include autoantibodies in type 
1 diabetes, new autoantigenic targets for CD4 T cells, trafficking of immune cells to 
the pancreas and islet-immune interactions in the pancreas.
Interaction within the immune system plays a central role in 
the development of type 1 diabetes, a complex autoimmune 
disease in which the insulin-producing beta cells of the pan-
creas are damaged and destroyed. Many discoveries have 
been made over the last few years, which have advanced our 
understanding of the pathogenesis of human type 1 diabe-
tes, aided by discoveries in animal models that include the 
much-studied non-obese diabetic (NOD) mouse. Type 1 
diabetes is a disease in which genetically susceptible indi-
viduals develop diabetes at a variable age, which can range 
from the very young (6 months), to over 70 years. In the 
United Kingdom, it is estimated that there are about 400,000 
people who have developed type 1 diabetes.
One of the earliest indicators that type 1 diabetes is 
an autoimmune disease was the measurement of autoan-
tibodies found in the serum, in the 1970s with the meas-
urement of islet-cell antibodies (ICA). Subsequently, more 
specific targets have been identified that include proinsulin, 
glutamic acid decarboxylase (GAD), islet antigen-2 (IA-2), 
Zinc Transporter 8 (ZnT8). In the 45-year history of islet 
autoantibody research, Bonifacio and Achenbach chronicle 
the discovery since the first publication in 1974, through 
to the current time, in which autoantibodies can be used 
to screen for individuals with presymptomatic early stage 
type 1 diabetes [1]. This is of considerable importance 
as we enter an era in which there are active clinical trials 
to find ways to stop the autoimmune process, and poten-
tially prevent disease. The identification of specific target 
antigens recognised by autoantibodies, led to the 
investigation and identification of the antigenic targets for 
autoreactive T cells. For the T cell target identification, 
the NOD mouse model has been particularly useful, with 
identification of autoantigenic targets in the mice, in which 
pathogenic T cells can be actually shown to damage islets 
recognising the targets. Whilst the antigenic targets for 
pathogenic CD8 T cells have been known for some years, 
the antigenic targets for CD4 T cells have been more 
elusive. The autoantigen recognized by one of the most 
studied highly pathogenic CD4 T cell clones BDC2.5, 
derived from the NOD mouse and which has given rise 
to many important insights into the role of CD4 T cells 
in type 1 diabetes, has only recently been identified. Delong 
and colleagues showed that the antigen was intriguingly, 
a hybrid peptide target that combines a proinsulin peptide 
with a peptide from chromogranin A, and they have 
described this in their review article in this issue [2]. 
Wiles and Delong discuss the discovery of hybrid peptides 
for CD4 T cell clones, including the observation that they 
are also antigenic for human CD4 T cells, as well as the 
mechanism by which these may be formed. It is highly 
possible that this mechanism may explain why identifica-
tion of the antigenic targets has been hitherto somewhat 
challenging and opens up a new way of thinking about 
the development of autoantigenic targets for autoimmunity 
in general.
Once autoreactive T cells are activated, they traffic to 
the pancreas, and enter to infiltrate the pancreatic islets 
of Langerhans, and damage the insulin-producing beta 
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cells. This is a key process in the pathogenic process 
and Sandor and colleagues review elegant studies in the 
NOD mouse, which demonstrate components of the 
pathogenic cell trafficking into the islets. They discuss 
the role of mononuclear phagocytic cells, that include 
dendritic cells, macrophages and monocytes, as well as 
the surface molecule and chemokine components that 
are required for this movement of the cells into the islets 
[3]. Understanding these processes may point to some 
new possibilities for therapeutic targeting as this may 
lead to less immunosuppression than non-antigen- 
specific targeting of individual cell types involved in the 
pathogenesis of diabetes.
In the final article in this series, Peters and colleagues 
have comprehensively reviewed immune cell – islet interac-
tions in type 1 diabetes, which lead to the damage and 
destruction of the insulin – producing beta cells. They discuss 
findings from both mouse models and human type 1 dia-
betes, with a major focus on what is known about patho-
logical processes in humans [4]. In recent years, the availability 
of human pancreas samples from individuals with type 1 
diabetes, together with advanced technologies, have facilitated 
considerable advance in our knowledge and understanding 
of the pathology of human type 1 diabetes. While there is 
clearly much to still be learned, we appreciate the informa-
tion that has been derived from the sign-posting from the 
mouse studies, that have opened the way to study and 
investigate similar pathologic processes in humans. This, in 
turn, may lead to an increase in the possible therapeutics 
for this complex multifactorial immune based disease.
Together these reviews give insight into both historical 
perspectives as well as recent advances in important research 
into the pathogenesis of type 1 diabetes, and summarise 
highlights of a field of research in which much progress 
has been made.
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